Liposomal-praziquantel: Efficacy Against Schistosoma Mansoni In A Preclinical Assay.

dc.creatorFrezza, Tarsila Ferraz
dc.creatorGremião, Maria Palmira Daflon
dc.creatorZanotti-Magalhães, Eliana Maria
dc.creatorMagalhães, Luiz Augusto
dc.creatorde Souza, Ana Luiza Ribeiro
dc.creatorAllegretti, Silmara Marques
dc.date2013-Oct
dc.date2015-11-27T13:31:53Z
dc.date2015-11-27T13:31:53Z
dc.date.accessioned2018-03-29T01:18:02Z
dc.date.available2018-03-29T01:18:02Z
dc.identifierActa Tropica. v. 128, n. 1, p. 70-5, 2013-Oct.
dc.identifier1873-6254
dc.identifier10.1016/j.actatropica.2013.06.011
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/23811113
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/200702
dc.identifier23811113
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1300935
dc.descriptionCurrently, schistosomiasis mansoni is treated clinically with praziquantel (PZQ). Nevertheless, cases of tolerance and resistance to this drug have been reported, creating the need to develop new drugs or to improve existing drugs. Considering the small number of new drugs against Schistosoma mansoni, the design of nanotechnology-based drug delivery systems is an important strategy in combating this disease. The aim of this study was to evaluate the activity of PZQ containing liposome (lip.PZQ) on S. mansoni, BH strain. Mice were treated orally with different concentrations of PZQ and lip.PZQ 30 and 45 days following infection. The number of worms, recovered by perfusion of the hepatic portal system, and the number of eggs found in the intestine and liver were analysed. Parasite egg counts were also performed. The most active formulation for all parameters was 300mg/kg of lip.PZQ, since as it decreased the total number of worms by 68.8%, the number of eggs in the intestine by 79%, and the number of hepatic granulomas by 98.4% compared to untreated controls. In addition, this concentration decreased egg counts by 55.5%. The improved efficacy of the treatment with lip.PZQ, especially when administered 45 days following infection, compared with the positive-control group (untreated) and the groups that received free PZQ, can be explained by greater bioavailability in the host organism; the preferred target of lip.PZQ is the liver, and lip.PZQ is better absorbed by the tegument of S. mansoni, which has an affinity for phospholipids.
dc.description128
dc.description70-5
dc.languageeng
dc.relationActa Tropica
dc.relationActa Trop.
dc.rightsfechado
dc.rightsCopyright © 2013 Elsevier B.V. All rights reserved.
dc.sourcePubMed
dc.subjectAnimals
dc.subjectAnthelmintics
dc.subjectBiological Availability
dc.subjectDisease Models, Animal
dc.subjectDrug Carriers
dc.subjectDrug Evaluation, Preclinical
dc.subjectFemale
dc.subjectIntestines
dc.subjectLiposomes
dc.subjectMale
dc.subjectMice
dc.subjectParasite Egg Count
dc.subjectParasite Load
dc.subjectPortal Vein
dc.subjectPraziquantel
dc.subjectSchistosoma Mansoni
dc.subjectSchistosomiasis Mansoni
dc.subjectTreatment Outcome
dc.subjectEncapsulation
dc.subjectIn Vivo Assay
dc.subjectLiposomes
dc.subjectPraziquantel
dc.subjectSchistosoma Mansoni
dc.titleLiposomal-praziquantel: Efficacy Against Schistosoma Mansoni In A Preclinical Assay.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución